ClassID:

20527

A61K31/7064 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Sub-classes:
Recent Application in this class:
#1
20260151462
2026-06-04

RECOMBINANT APYRASE PROTEIN FOR USE IN THE TREATMENT OF AN ISCHEMIC EVENT AT A DOSE OF 40-240 MG

#2
20260151415
2026-06-04

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

#3
20260146059
2026-05-28

MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF

#4
20260137688
2026-05-21

METHODS AND COMPOSITIONS FOR INHIBITION OF POLYMERASE

#5
20260115217
2026-04-30

TREATMENT OF ONCOGENE-DRIVEN CANCERS

#6
20260083766
2026-03-26

METHODS TO TREAT NEURODEGENERATIVE DISORDERS BY REDUCING NUCLEAR AGGREGATES AND MODULATING ADENOSINE-TO-INOSINE RNA EDITING

#7
20260060943
2026-03-05

OVARIAN CANCER VACCINES

#8
20260049145
2026-02-19

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

#9
20260035403
2026-02-05

NUCLEOSIDE LINE-1 INHIBITORS

#10
20260007675
2026-01-08

TARGETING CHROMATIN REGULATORS INHIBITS LEUKEMOGENIC GENE EXPRESSION IN NPM1 MUTANT LEUKEMIA

#11
20260000698
2026-01-01

SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS

#12
20250361258
2025-11-27

PROCESSES FOR MAKING PRMT5 INHIBITORS

#13
20250320245
2025-10-16

Nucleoside Analogues for the Treatment of Parasitic Infections

#14
20250319113
2025-10-16

INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE

#15
20250313588
2025-10-09

NOVEL PYRROLOPYRIMIDINONE CARBOXAMIDE COMPOUND FOR INHIBITING CDK, STEREOISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT

#16
20250213603
2025-07-03

PHARMACEUTICAL COMPOSITION FOR TREATING CANCER

#17
20250188110
2025-06-12

SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION

#18
20250177428
2025-06-05

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

#19
20250170118
2025-05-29

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WET AGE-RELATED MACULAR DEGENERATION

#20
20250154163
2025-05-15

Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors

#21
20250144125
2025-05-08

6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES

#22
20250092080
2025-03-20

FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES

#23
20250084119
2025-03-13

PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF

#24
20250082663
2025-03-13

COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE (ADPLD) AND/OR AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)

#25
20250066411
2025-02-27

GLYCOMIMETIC BINDERS FOR L-SIGN

#26
20250049833
2025-02-13

ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASE

#27
20240392382
2024-11-28

MUTATIONAL MARKERS IN PANCREATIC NEUROENDOCRINE TUMORS FOR USE IN STRATIFYING RESPONSE TO CAPECITABINE/TEMOZOLOMIDE

#28
20240374740
2024-11-14

POLY AMPHIPHILIC COMPLEXES FOR THE DELIVERY OF A HYDROPHOBIC ACTIVE AGENT, COMPOSITIONS AND METHODS

#29
20240368204
2024-11-07

SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF

#30
20240352057
2024-10-24

MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF

#31
20240300991
2024-09-12

NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME

#32
20240287124
2024-08-29

PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

#33
20240285665
2024-08-29

Inhibitors of adenosine 5′-nucleotidase

#34
20240277640
2024-08-22

COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORONAVIRUS AND RELATED DISORDERS

#35
20240270780
2024-08-15

PROTEOLYSIS TARGETING COMPOUND WITH TISSUE TARGETING CAPABILITY AND USE THEREOF

#36
20240261316
2024-08-08

HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19

#37
20240238324
2024-07-18

Highly active compounds against COVID-19

#38
20240238323
2024-07-18

MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES

#39
20240226165
2024-07-11

Methods of Producing Improved Immune Cell Populations

#40
20240226000
2024-07-11

TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS

#41
20240216414
2024-07-04

Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus

#42
20240207299
2024-06-27

PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION

#43
20240139227
2024-05-02

Nucleoside phosphoramidate prodrugs

#44
20240131046
2024-04-25

ANTI-VIRAL AGENT

#45
20240130962
2024-04-25

TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS

#46
20240108734
2024-04-04

METHODS FOR TREATING AND AMELIORATING CANCER

#47
20240059772
2024-02-22

DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS

#48
20240041798
2024-02-08

OVARIAN CANCER VACCINES

#49
20240009222
2024-01-11

Administration of nicotinamide mononucleotide in the treatment of disease

#50
20230285434
2023-09-14

METHOD FOR TREATING ARENAVIRIDAE INFECTIONS

#51
20230241087
2023-08-03

Methods Of Treating Cancer Using Prmt5 Inhibitors

#52
20230234984
2023-07-27

Cysteine protease inhibitors and methods of use thereof

#53
20230233591
2023-07-27

METHOD FOR TREATING POXVIRIDAE INFECTIONS

#54
20230218654
2023-07-13

COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA IN TYPE-2 DIABETES

#55
20230218620
2023-07-13

Compositions and methods for treating retinal degradation

#56
20230201233
2023-06-29

USE OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, AND NICOTINAMIDE MONONUCLEOTIDE, REDUCED NICOTINYL COMPOUNDS, AND NICOTINOYL COMPOUND DERIVATIVES IN INFANT FORMULA FOR HEALTHY DEVELOPMENT

#57
20230172933
2023-06-08

USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION

#58
20230172882
2023-06-08

Method For Treating Pancreatic Cancer

#59
20230158054
2023-05-25

METHODS, COMPOSITIONS, AND DOSING REGIMENS FOR TREATMENT OF SARS-COV-2 INFECTIONS

#60
20230142547
2023-05-11

COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION

#61
20230114280
2023-04-13

COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS

#62
20230104311
2023-04-06

NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS

#63
20230095103
2023-03-30

COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF LUNG DISEASES AND CONDITIONS

#64
20230079150
2023-03-16

METHODS FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED ORGAN INJURY OR FAILURE WITH IL-22 DIMER

#65
20230039099
2023-02-09

AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE

#66
20230033327
2023-02-02

COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

#67
20230012655
2023-01-19

URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF

#68
20230000893
2023-01-05

Antiviral agents and nucleoside analogs for treatment of Zika virus

#69
20220395575
2022-12-15

COMBINATION THERAPY WITH PROTEIN KINASE B ACTIVATION INHIBITOR TO TREAT CANCER

#70
20220378815
2022-12-01

Method for treating coronavirus infections

#71
20220347200
2022-11-03

Highly active compounds against COVID-19

#72
20220347199
2022-11-03

Highly active compounds against COVID-19

#73
20220339180
2022-10-27

Methods And Compositions For Treating Viral Diseases Using Combination Of Drugs

#74
20220323573
2022-10-13

METHODS FOR TREATING COVID-19 BASED ON INDIVIDUAL GENOMIC PROFILES

#75
20220280513
2022-09-08

ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM

#76
20220259253
2022-08-18

CD73 INHIBITORS

#77
20220251212
2022-08-11

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

#78
20220248666
2022-08-11

Compositions and methods for preserving red blood cells and platelets

#79
20220241313
2022-08-04

TREATMENT OF ONCOGENE-DRIVEN CANCERS

#80
20220233566
2022-07-28

NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

#81
20220218732
2022-07-14

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

#82
20220184111
2022-06-16

METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY

#83
20220160664
2022-05-26

TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS

#84
20220153747
2022-05-19

Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)

#85
20220152073
2022-05-19

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

#86
20220152072
2022-05-19

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

#87
20220135611
2022-05-05

URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE

#88
20220135609
2022-05-05

Mannose derivatives for treating bacterial infections

#89
20220096513
2022-03-31

Compounds and methods useful for treating or preventing cancers

#90
20220054495
2022-02-24

Compositions and methods for enhanced delivery of antiviral agents

#91
20220047597
2022-02-17

Madrasin-derivative compounds, composition and uses thereof for treating cancer

#92
20220040190
2022-02-10

Methods and Compositions for Inhibition of Polymerase

#93
20220002396
2022-01-06

METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS

#94
20220002335
2022-01-06

Pyrrolopyrimidine nucleosides and analogs thereof

#95
20210393663
2021-12-23

PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR OR ITS ANALOG FOR INHALATION

#96
20210379171
2021-12-09

Ovarian cancer vaccines

#97
20210379155
2021-12-09

Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases

#98
20210371449
2021-12-02

Modulators of 5′-nucleotidase, ecto and the use thereof

#99
20210346413
2021-11-11

Administration of nicotinamide mononucleotide in the treatment of disease

#100
20210346281
2021-11-11

Multi-component injection

#101
20210330732
2021-10-28

METHOD OF MAKING SOLANACEAE FRUIT EXTRACTS

#102
20210275563
2021-09-09

Highly active compounds against COVID-19

#103
20210252035
2021-08-19

SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS

#104
20210236497
2021-08-05

Method for treating coronavirus infections

#105
20210228604
2021-07-29

Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

#106
20210205253
2021-07-08

Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis

#107
20210196741
2021-07-01

Nucleoside phosphoramidate prodrugs

#108
20210154221
2021-05-27

4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF

#109
20210128599
2021-05-06

Methods and agents for modulating inflammation

#110
20210122776
2021-04-29

COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

#111
20210106604
2021-04-15

Substituted nucleosides, nucleotides and analogs thereof

#112
20210085681
2021-03-25

Compositions and methods for treating retinal degradation

#113
20210069226
2021-03-11

Uridine diphosphate derivatives, prodrugs, compositions and uses thereof

#114
20210053981
2021-02-25

ANTIVIRAL COMPOUNDS

#115
20210046023
2021-02-18

Persistent topical antimicrobial compositions and methods of using the same

#116
20210023077
2021-01-28

Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor

#117
20210009682
2021-01-14

REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS

#118
20210002322
2021-01-07

Modulators of 5′-nucleotidase, ecto and the use thereof

#119
20200399302
2020-12-24

Uridine nucleoside derivatives, compositions and methods of use

#120
20200390795
2020-12-17

DIETARY SUPPLEMENT COMPOSITIONS FOR TREATING HYPERTENSION AND METHODS OF USING SAME FOR TREATING HYPERTENSION

#121
20200385460
2020-12-10

Diagnosis and therapy of cancer involving cancer stem cells

#122
20200385340
2020-12-10

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS

#123
20200384006
2020-12-10

Methods of treating cancer using PRMT5 inhibitors

#124
20200383318
2020-12-10

Compositions and methods for preserving red blood cells and platelets

#125
20200361946
2020-11-19

Selective inhibitors of protein arginine methytransterase 5 (PRMT5)

#126
20200353080
2020-11-12

Cancer therapeutic methods utilizing OPCML fragment

#127
20200347090
2020-11-05

CD73 inhibitors

#128
20200289539
2020-09-17

Substituted nucleoside analogues for use as PRMT5 inhibitors

#129
20200289534
2020-09-17

Method of treating, reducing, or alleviating a medical condition in a patient

#130
20200277655
2020-09-03

Tools for assessing FimH blockers therapeutic efficiency

#131
20200270293
2020-08-27

2,7-dibromospiro[fluorene-9,4′-piperidine] compounds

#132
20200268753
2020-08-27

PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS

#133
20200239963
2020-07-30

Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition

#134
20200239921
2020-07-30

CHEMOENZYMATIC SYNTHESIS OF S-NUCLEOSYL AMINO ACIDS (SNA), ANALOGS OF S-ADENOSYL-L-METHIONINE AND S-ADENOSYL-L- HOMOCYSTEINE AND USES THEREOF

#135
20200237689
2020-07-30

PREVENTION AND TREATMENT OF CORONAVIRUS AND OTHER RESPIRATORY INFECTIONS USING NANOEMULSION COMPOSITIONS

#136
20200222441
2020-07-16

Inhibitors of adenosine 5′-nucleotidase

#137
20200199167
2020-06-25

Pyrrolopyrimidine nucleosides and analogs thereof

#138
20200188404
2020-06-18

Methods of treating and inhibiting Ebola virus infection

#139
20200155588
2020-05-21

Drug formulations

#140
20200148692
2020-05-14

Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)

#141
20200113923
2020-04-16

DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA

#142
20200071337
2020-03-05

ANTIVIRAL COMPOUNDS

#143
20200041488
2020-02-06

Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA

#144
20200030355
2020-01-30

COMBINATION THERAPY FOR TREATING CANCER

#145
20190374559
2019-12-12

Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating induced inflammatory bowel diseases such as crohn's disease

#146
20190374544
2019-12-12

Methods and compositions for inhibition of polymerase

#147
20190364882
2019-12-05

Compositions and methods for preserving red blood cells and platelets

#148
20190328758
2019-10-31

Methods of treating mitochondrial dysfunction

#149
20190314395
2019-10-17

USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE

#150
20190309010
2019-10-10

Modulators of 5′-nucleotidase, ecto and the use thereof

#151
20190307750
2019-10-10

Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia

#152
20190276899
2019-09-12

DOT1L INHIBITION IN PATIENTS WITH MN1-HIGH AML

#153
20190276468
2019-09-12

Antiviral compounds

#154
20190269609
2019-09-05

A MULTI-COMPONENT INJECTION

#155
20190255049
2019-08-22

Compositions and methods for treating retinal degradation

#156
20190247412
2019-08-15

Cancer chemotherapy employing halogenated analogs of thymidine

#157
20190240228
2019-08-08

Purine derivative for use in the treatment or prevention of diseases caused by a nonsense mutation

#158
20190225684
2019-07-25

REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS

#159
20190224223
2019-07-25

Administration of nicotinamide mononucleotide in the treatment of disease

#160
20190185508
2019-06-20

DEUTERATED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

#161
20190134173
2019-05-09

Ovarian cancer vaccines

#162
20190125748
2019-05-02

Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

#163
20190119684
2019-04-25

Methods for improving cognitive function via modulation of quinone reductase 2

#164
20190106450
2019-04-11

Mannose derivatives for treating bacterial infections

#165
20190105384
2019-04-11

Treatment and prevention of anal conditions

#166
20190100552
2019-04-04

INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF

#167
20190091253
2019-03-28

Therapies for cardiomyopathy

#168
20190054108
2019-02-21

Substituted nucleosides, nucleotides and analogs thereof

#169
20190048084
2019-02-14

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

#170
20190038597
2019-02-07

PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION

#171
20190031732
2019-01-31

Compositions and methods for treating cancers

#172
20190031623
2019-01-31

Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

#173
20190022122
2019-01-24

Carboline derivatives or phosphorous derivatives for the treatment of muscular myopathies and traumatic injuries to muscles

#174
20190022115
2019-01-24

4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof

#175
20180369267
2018-12-27

Drug formulations

#176
20180360836
2018-12-20

Methods and compositions for inhibition of polymerase

#177
20180360022
2018-12-20

Compositions and methods for preserving red blood cells and platelets

#178
20180346991
2018-12-06

HEATR1 as a marker for chemoresistance

#179
20180346572
2018-12-06

Anti-PD-L1 combinations for treating tumors

#180
20180338991
2018-11-29

NAD BIOSYNTHESIS AND PRECURSORS FOR THE TREATMENT AND PREVENTION OF CANCER AND PROLIFERATION

#181
20180296684
2018-10-18

TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE

#182
20180280422
2018-10-04

SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS

#183
20180280421
2018-10-04

Uridine diphosphate derivatives, prodrugs, compositions and uses thereof

#184
20180258129
2018-09-13

Alkynyl nucleoside analogs as inhibitors of human rhinovirus

#185
20180256666
2018-09-13

Method of making solanaceae fruit extracts

#186
20180244712
2018-08-30

Cyclic di-nucleotide compounds as STING agonists

#187
20180244683
2018-08-30

ANTIVIRAL COMPOUNDS

#188
20180237469
2018-08-23

Cyclic di-nucleotide compounds as sting agonists

#189
20180235993
2018-08-23

METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES

#190
20180230178
2018-08-16

Cyclic di-nucleotide compounds as STING agonists

#191
20180194792
2018-07-12

COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

#192
20180186806
2018-07-05

ANTIVIRAL COMPOUNDS

#193
20180127451
2018-05-10

Substituted purine compounds

#194
20180125875
2018-05-10

Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells

#195
20180118724
2018-05-03

Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof

#196
20180099989
2018-04-12

Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof

#197
20180064744
2018-03-08

Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes

#198
20180050054
2018-02-22

Administration of nicotinamide mononucleotide in the treatment of disease

#199
20180044369
2018-02-15

Substituted nucleosides, nucleotides and analogs thereof

#200
20180042933
2018-02-15

Treatment of ACVR1-mediated diseases

#201
20180015163
2018-01-18

Cancer methods

#202
20180002366
2018-01-04

4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

#203
20180000855
2018-01-04

Nucleoside phosphoramidate prodrugs

#204
20180000824
2018-01-04

Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor

#205
20170362170
2017-12-21

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS

#206
20170348343
2017-12-07

Methods of treating hepatitis E viral infection

#207
20170319612
2017-11-09

INHIBITION OF NONSENSE MEDIATED MRNA DECAY BY DRUGS THAT PREVENT HYPUSINATION OF EUKARYOTIC INITIATION FACTOR 5A

#208
20170313736
2017-11-02

MUTAGENIC NUCLEOSIDE ANALOGS AND USES THEREOF

#209
20170296564
2017-10-19

Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

#210
20170281665
2017-10-05

Methods of treating breast cancer that overexpress AKT kinase

#211
20170275329
2017-09-28

Alkynyl nucleoside analogs as inhibitors of human rhinovirus

#212
20170267710
2017-09-21

Modulators of 5′-nucleotidase, ecto and the use thereof

#213
20170253628
2017-09-07

Pyrrolopyrimidine nucleosides and analogs thereof

#214
20170247343
2017-08-31

THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE

#215
20170240584
2017-08-24

7-deazapurine nucleosides for therapeutic uses

#216
20170232030
2017-08-17

COMBINATION THERAPY FOR TREATING CANCER

#217
20170216338
2017-08-03

Cancer chemotherapy employing halogenated analogs of thymidine

#218
20170216337
2017-08-03

Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof

#219
20170204101
2017-07-20

Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof

#220
20170196902
2017-07-13

Application of cyclic dinucleotide (cGAMP) in anti-tumor field

#221
20170191057
2017-07-06

RNA EDITING BIOMARKERS FOR DIAGNOSIS, PHARMACOLOGICAL SCREENING AND PROGNOSTICATION IN CANCER

#222
20170173065
2017-06-22

Antiviral composition containing material involved in phosphatidylcholine synthesis pathway

#223
20170143751
2017-05-25

Substituted nucleosides, nucleotides and analogs thereof

#224
20170137455
2017-05-18

Inhibitors of protein methyltransferase DOT1L and methods of use thereof

#225
20170137454
2017-05-18

Pyrrolopyrimidine nucleosides and analogs thereof

#226
20170107247
2017-04-20

UBA5 inhibitors

#227
20170095497
2017-04-06

TRANSIENT INHIBITION OF ADENOSINE KINASE AS AN ANTI-EPILEPTOGENESIS TREATMENT

#228
20170088573
2017-03-30

Gemcitabine analogs

#229
20170081669
2017-03-23

Methods for improving cognitive function via modulation of quinone reductase 2

#230
20170080007
2017-03-23

EFFECTIVE TREATMENT OF ESOPHAGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS

#231
20170051004
2017-02-23

Sofosbuvir in crystalline form and process for its preparation

#232
20170044206
2017-02-16

Cyclic di-nucleotide compounds as sting agonists

#233
20170044205
2017-02-16

3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

#234
20170042927
2017-02-16

Effective treatment of ovarian cancer using triciribine and related compounds

#235
20170042901
2017-02-16

Methods and compositions for inhibition of polymerase

#236
20170035676
2017-02-09

External dermatological agent for anti-ageing

#237
20170029456
2017-02-02

Nucleotides for the treatment of liver cancer

#238
20160368943
2016-12-22

Substituted purine compounds

#239
20160361338
2016-12-15

Compositions of selenoorganic compounds and methods of use thereof

#240
20160354476
2016-12-08

Targeted therapeutic nucleosides and their use

#241
20160346310
2016-12-01

Drug formulations

#242
20160340445
2016-11-24

Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating induced inflammatory bowel diseases such as crohn's disease

#243
20160318970
2016-11-03

7-deazapurine nucleosides for therapeutic uses

#244
20160318969
2016-11-03

Solid forms of a thiophosphoramidate nucleotide prodrug

#245
20160298195
2016-10-13

Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition

#246
20160296546
2016-10-13

Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof

#247
20160280735
2016-09-29

2′,4′-substituted nucleosides as antiviral agents

#248
20160272643
2016-09-22

5′-nucleotidase inhibitors and therapeutic uses thereof

#249
20160263140
2016-09-15

USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE

#250
20160263114
2016-09-15

Compositions and methods for treating retinal degradation

#251
20160244475
2016-08-25

Substituted nucleoside derivatives useful as anticancer agents

#252
20160244473
2016-08-25

2′, 5′-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof

#253
20160243148
2016-08-25

Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders

#254
20160237158
2016-08-18

Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis

#255
20160235775
2016-08-18

Mannose derivatives for treating bacterial infections

#256
20160222050
2016-08-04

Mutagenic nucleoside analogs and uses thereof

#257
20160220597
2016-08-04

Uridine and uridine analogues for treatment of specific lung diseases, namely COPD and pulmonary fibrosis

#258
20160220538
2016-08-04

Identification of small molecules that facilitate therapeutic exon skipping

#259
20160206644
2016-07-21

Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof

#260
20160176911
2016-06-23

Substituted nucleosides, nucleotides and analogs thereof

#261
20160166599
2016-06-16

Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient

#262
20160159901
2016-06-09

Diagnosis and therapy of cancer involving cancer stem cells

#263
20160159843
2016-06-09

Nucleoside and nucleotide derivatives

#264
20160158368
2016-06-09

METHODS AND COMPOSITIONS FOR THE TREATMENT OF HISTIOCYTOSIS

#265
20160158266
2016-06-09

2′ Fluoronucleosides

#266
20160157478
2016-06-09

Compositions and methods for preserving donated blood

#267
20160151494
2016-06-02

Targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof

#268
20160145289
2016-05-26

Compounds and methods for treating bacterial infections

#269
20160136273
2016-05-19

Compositions including triciribine and trastuzumab and methods of use thereof

#270
20160136228
2016-05-19

Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof

#271
20160130294
2016-05-12

Deuterated nucleoside/tide derivatives

#272
20160129032
2016-05-12

Substituted quinazolines as receptor-type kinase inhibitors

#273
20160122380
2016-05-05

Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

#274
20160115189
2016-04-28

PARASITICIDAL COMPOUNDS, METHODS, AND FORMULATIONS

#275
20160106771
2016-04-21

THERAPIES FOR CARDIOMYOPATHY

#276
20160102366
2016-04-14

Method for predicting therapeutic efficacy of PI3K/AKT/mTOR inhibitor on basis of PHLDA1 or PIK3C2B expression

#277
20160100618
2016-04-14

Method for stimulating the intestinal flora

#278
20160095844
2016-04-07

Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives

#279
20160082033
2016-03-24

Compositions of selenoorganic compounds and methods of use thereof

#280
20160082031
2016-03-24

Antitumor agent including low-dose irinotecan hydrochloride hydrate

#281
20160075731
2016-03-17

Uridine nucleoside derivatives, compositions and methods of use

#282
20160058806
2016-03-03

METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH

#283
20160058783
2016-03-03

Nucleoside and nucleotide derivatives

#284
20160045532
2016-02-18

Methods for modulating chemotherapeutic cytotoxicity

#285
20160045531
2016-02-18

COMBINATION THERAPY FOR TREATING CANCER

#286
20160045530
2016-02-18

Antitumor agent including irinotecan hydrochloride hydrate

#287
20160022723
2016-01-28

Combination therapy for the treatment of proliferative diseases

#288
20160022712
2016-01-28

Administration of nicotinamide mononucleotide in the treatment of disease

#289
20160000818
2016-01-07

Compositions including triciribine and one or more platinum compounds and methods of use thereof

#290
20150374737
2015-12-31

Dual-action compounds targeting adenosine Areceptor and adenosine transporter for prevention and treatment of neurodegenerative diseases

#291
20150374704
2015-12-31

Combined systemic and topical treatment of disordered and/or prodromal stage tissue

#292
20150366893
2015-12-24

SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS

#293
20150366892
2015-12-24

Method using heat shock protein inhibitor for treating hepatitis and hepatoma

#294
20150359813
2015-12-17

Effective treatment of esophageal adenocarcinoma using triciribine and related compounds

#295
20150344889
2015-12-03

Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias

#296
20150342979
2015-12-03

DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA

#297
20150342955
2015-12-03

Combined systemic and topical treatment of disordered tissues

#298
20150335053
2015-11-26

Preventing diseases in infants delivered via caesarean section

#299
20150320784
2015-11-12

Effective treatment of tumors and cancer with triciribine and related compounds

#300
20150313930
2015-11-05

NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation